Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cochlear-ltd" target="_blank" data-smartkarma-citation="entities:918:1" rel="noopener">Cochlear Ltd (COH AU)</a> shares rallied 30%+ over the last six months. Shares are trading at NTM P/E of 51.3x, versus other Australia-listed medical devices companies’ P/E of 23–32x.</li>
<li>The underlying business strength depicted by strong financial performance and guidance raise, and superior product offerings justify the pricey valuation.</li>
<li>Cochlear lifted FY24 net profit guidance to A$385–400M (+26–31% YoY) from A$355–375M. The company expects FY24 cochlear implant volume growth of 10–15% YoY.</li>
</ul>



Cochlear Ltd (COH AU) shares rallied 30%+ over the last six months. Shares are trading at NTM P/E of 51.3x, versus other Australia-listed medical devices companies’ P/E of 23–32x.
The underlying business strength depicted by strong financial performance and guidance raise, and superior product offerings justify the pricey valuation.
Cochlear lifted FY24 net profit guidance to A$385–400M (+26–31% YoY) from A$355–375M. The company expects FY24 cochlear implant volume growth of 10–15% YoY.


Cochlear Ltd (COH AU): Underlying Business Strength Justifies Superior Valuation

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>ResMed Inc. delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.</li><li>Group revenue reached $1.12 billion, reflecting a notable 23% increase on a headline basis and in constant currency.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

ResMed Inc. delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street.Group revenue reached $1.12 billion, reflecting a notable 23% increase on a headline basis and in constant currency.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

ResMed Inc.: Will The Acquisition of Somnoware Up The Respiratory Diagnostics Game? - Major Drivers

Quantitative Researcher, MRM Research

Nico Rosti

Quantitative Researcher

MRM Research

Quantitative Research

Event-Driven

<ul>
<li>The <a href="https://www.smartkarma.com/entities/s-p-asx-200" target="_blank" data-smartkarma-citation="entities:22901:1" rel="noopener">S&amp;P/ASX 200 INDEX</a> has been stuck in the 7000-7400 range for the past 16 weeks.</li>
<li>If the index continues to be trendless for some more weeks, it's possible to profit from repeatedly writing Covered Calls against ASX 200 index holdings.</li>
<li>Strike target areas for Covered Calls begin in the 7319-7409 (July 20 expiry). Deeper OTM Strikes are safe,  but the premiums are smaller.</li>
</ul>


The S&amp;P/ASX 200 INDEX has been stuck in the 7000-7400 range for the past 16 weeks.
If the index continues to be trendless for some more weeks, it's possible to profit from repeatedly writing Covered Calls against ASX 200 index holdings.
Strike target areas for Covered Calls begin in the 7319-7409 (July 20 expiry). Deeper OTM Strikes are safe,  but the premiums are smaller.


EQD | S&P/ASX200: Ideas to Profit From a Directionless Market

Equity Capital Markets

<ul><li>ResMed delivered a strong set of financial results in the last quarter and managed an all-around beat.</li><li>While they are still addressing some supply chain challenges with the AirSense 11 platform, they are on track to meet the global demand for connected CPAP and APAP devices by the end of 2023.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

ResMed delivered a strong set of financial results in the last quarter and managed an all-around beat.While they are still addressing some supply chain challenges with the AirSense 11 platform, they are on track to meet the global demand for connected CPAP and APAP devices by the end of 2023.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

ResMed Inc.: On Track to Meet Global Demand for Connected CPAP and APAP Devices – Key Drivers

High Quality Stock Setups, Weekly Stock Bull Finder

Weekly Stock Bull Finder

High Quality Stock Setups

Finding high potential stock setups on quality companies

Thematic (Sector/Industry)

<ul><li>When considering future investment opportunities, the renewable energy transition continues to be an exciting space to investors given its enormous potential total addressable market coupled with climate change legislation that is acting as a tailwind in virtually every G-20 country.</li><li>Almost every month, there continues to be a steady drumbeat of new rules issued locally and across the globe which results in faster timelines to transition to battery storage and other clean energy as well as tighter restrictions to ultimately phase out traditional gas powered transportation and coal power.</li><li>For example, while California has already passed rules requiring all new cars, pickup trucks and SUVs sold to be electric or hydrogen by 2035, California approved rules last week which will require all new medium heavy-duty truck and bus sales sold in the state in 2036 to be zero-emission</li></ul>

When considering future investment opportunities, the renewable energy transition continues to be an exciting space to investors given its enormous potential total addressable market coupled with climate change legislation that is acting as a tailwind in virtually every G-20 country.Almost every month, there continues to be a steady drumbeat of new rules issued locally and across the globe which results in faster timelines to transition to battery storage and other clean energy as well as tighter restrictions to ultimately phase out traditional gas powered transportation and coal power.For example, while California has already passed rules requiring all new cars, pickup trucks and SUVs sold to be electric or hydrogen by 2035, California approved rules last week which will require all new medium heavy-duty truck and bus sales sold in the state in 2036 to be zero-emission

United States

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ResMed Inc (RMD AU)

Cochlear Ltd (COH AU): Underlying Business Strength Justifies Superior Valuation

Cochlear lifted FY24 net profit guidance 8% to A$385–400M (+26–31% YoY). The company expects FY24 cochlear implant volume growth of 10–15% YoY from...

Tina Banerjee

ResMed Inc.: Will The Acquisition of Somnoware Up The Respiratory Diagnostics Game? - Major Drivers

ResMed Inc. delivered a disappointing set of results as the company was unable to meet the revenue and earnings expectations of Wall Street. Group...

Baptista Research

EQD | S&P/ASX200: Ideas to Profit From a Directionless Market

Overall it seems the index for now is respecting the prediction we made 3 weeks ago: directionless, shortable - but also you can go LONG when the...

Nico Rosti

ResMed Inc.: On Track to Meet Global Demand for Connected CPAP and APAP Devices – Key Drivers

ResMed delivered a strong set of financial results in the last quarter and managed an all-around beat. While they are still addressing some supply...

Baptista Research

Weekly Stock Bullfinder - Week of 5/1

When considering future investment opportunities, the renewable energy transition continues to be an exciting space to investors given its enormous...

Weekly Stock Bull Finder

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)